Medical insurance reimbursement amount for ruxolitinib tablets/ruxolitinib

Ruxolitinib tablets/Ruxolitinib (Ruxolitinib), marketed in China as "ruxolitinib phosphate tablets", is a type of JAK inhibitor widely used in blood system diseases. Its advent has brought new treatment options to patients with myelofibrosis, polycythemia vera and graft-versus-host disease. However, because the drug is an imported original targeted drug, the price has always been the topic of greatest concern to patients. With the advancement of national medical insurance negotiations, ruxolitinib has been included in Category B of the medical insurance catalog, which means that patients can reduce the financial burden of medication under the coverage of the reimbursement policy.

In the domestic market, common specifications of ruxolitinib include20mg 14 tablets and 5mg 60 tablets. Before reimbursement, the price of a box of medicine is about 3,000 yuan. If calculated based on long-term oral administration, the annual cost is not a small burden for the patient's family. After being included in Category B medical insurance, the reimbursement ratio varies from region to region. Generally, patients are required to pay a certain proportion of the out-of-pocket amount first, and then the medical insurance fund pays the remaining portion in proportion. For patients undergoing long-term treatment for chronic diseases, medical insurance reimbursement has greatly improved the accessibility of drugs.

In contrast, in overseas markets, in developed countries such as the United States, the price of ruxolitinib is generally high, with the monthly cost often exceeding several thousand dollars, and patients often need to rely on commercial insurance or assistance programs. In China, due to the coverage of medical insurance policies and the gradual advancement of national centralized procurement, this type of innovative drugs has entered clinical routine use faster.

It should be noted that the amount of medical insurance reimbursement is not fixed, and different provinces may have differences in implementation details. In some areas, the coverage ratio for major diseases is higher, and the patient's out-of-pocket portion is relatively reduced. As the medical insurance catalog continues to adjust, the price of ruxolitinib may still fall further in the future.

Reference materials:https://www.jakavi.com/